Skip to main content
. 2024 Sep 19;15:1456565. doi: 10.3389/fphar.2024.1456565

TABLE 4.

Tacrolimus population pharmacokinetic parameter estimates and bootstrap results for the final model a .

Parameter Units Final model parameter estimate (RSE%) Median (95% CI) bootstrap result**
Disposition parameters
CL/F =θ1·θ2θ3·AGE·agecat·BW/700.75
θ1 L/h/70 kg 26.5 (7.8%) 26.4 (22.7–30.7)
θ2 0.666 (8.1%) 0.663 (0.579–0.759)
θ3 L/h/70 kg/y 0.0562(26.0%) 0.0560 (0.0266–0.0863)
Vc/F L/70 kg 327(14.0%)) 326 (259–479)
Vp/F L 298 (17.4%) 304 (164–468)
CLD/F L/h/70 kg 51.9 (27.0%) 53.5 (29.9–98.5)
Absorption parameters
Ka h−1 2.0 FIX
Lag-time h 0.341 (9.4%) 0.346 (0.255–0.413)
Between-patient variability
ω2 CL % 32.1(15.1%) 31.5 (26.9–37.2)
ω2 Vc % 48.2(75.4%) 46.4 (19.2–99.9)
Residual variability % 28.2(3.8%) 27.7 (24.8–30.1)
a

CL/F, apparent blood elimination clearance; CLD/F, apparent inter-compartmental clearance between central and peripheral compartments; Vc/F and Vp/F, apparent distribution volumes of the central and peripheral compartments; Ka, first-order absorption rate constant; F, bioavailability; σ2, proportional residual variability expressed as the coefficient of variation; ω2, variance of between patient variabilities associated with the PK parameters, expressed as the coefficient of variation. θ2, change of CL/F values in CYP3A5*1 non-carriers with respect to CL/F values in CYP3A5*1 carriers; BW, bodyweight in kg; AGE, age in years; agecat, categorical variable that equals 0 for patients 60 years old and younger and equals 1 for patients older than 60 years; CL/F, CLD/F, and Vc/F were allometrically scaled to 70 kg of bodyweight; allometric exponents were fixed to 0.75 for flow pharmacokinetic parameters and to 1 for central compartment distribution volume as follows, CL/F =θ1·θ2θ3·AGE·agecat·BW/700.75 ; CLD/F =θ5·BW/700.75 ; Vc/F =θ4·BW/70 .

**Estimated from 500 re-samplings with the non-parametric bootstrap method.